

PI Industries

Estimate change	↔
TP change	↑
Rating change	↔

Motilal Oswal values your support in the Asiamoney Brokers Poll 2020 for India Research, Sales and Trading team. We [request your ballot.](#)



Bloomberg	PI IN
Equity Shares (m)	138
M.Cap.(INRb)/(USDb)	219.7 / 3
52-Week Range (INR)	1649 / 974
1, 6, 12 Rel. Per (%)	-5/22/58
12M Avg Val (INR M)	238

Financials & Valuations (INR b)

Y/E Mar	2020	2021E	2022E
Sales	33.7	44.8	53.7
EBITDA	7.2	9.8	12.5
PAT	4.6	6.4	8.4
EBITDA (%)	21.3	21.9	23.3
EPS (INR)	33.1	46.1	61.2
EPS Gr. (%)	11.3	39.1	32.8
BV/Sh. (INR)	190	228	281

Ratios

Net D/E	0.1	0.1	0.1
RoE (%)	18.6	22.0	24.0
RoCE (%)	17.3	19.5	21.8
Payout (%)	14.7	17.2	13.0

Valuations

P/E (x)	48.1	34.5	26.0
EV/EBITDA (x)	31.1	22.7	17.7
Div Yield (%)	0.3	0.4	0.4
FCF Yield (%)	(0.1)	0.4	1.7

Shareholding pattern (%)

As On	Mar-20	Dec-19	Mar-19
Promoter	51.4	51.4	51.4
DII	21.6	20.5	19.0
FII	12.2	13.9	13.3
Others	14.8	14.3	16.3

FII Includes depository receipts

CMP: INR1,591 **TP: INR1,835 (+15%)** **Buy**

Entry into pharma value chain – a key positive

Earnings below estimates; COVID-19 disrupts operations

- Operating performance of PI Industries (PI) was subdued due to the COVID-19 pandemic, resulting in deferment of revenue. This in turn, led to decline in domestic agrochemicals' segment with some growth moderation in Custom Synthesis and Manufacturing (CSM) business.
- PI has successfully marked its entry into the pharma value chain, which it has worked on since the last 4-5 years. The company has tied up with a few large pharma companies in Japan and India (supplies should start from 1QFY21), which we believe is a commendable feat.
- We maintain our estimates for FY21/FY22E and value the stock at 30x FY22E EPS to arrive at a TP of INR1,835, implying 15% upside.

CSM saves the day

- 4QFY20 revenue of INR8.6b (v/s est. INR9.6b) was up 6% YoY (incl. Isagro's performance, which was absent in the base quarter). EBITDA stood at INR1.86b (v/s est. INR2.08b), up 7% YoY; EBITDA margins expanded 20bp YoY to 21.8% (v/s est. 21.6%). However, adj. PAT declined 12% YoY to INR1,107m (v/s est. INR1,478m). This was on account of lower other income and increase in depreciation and interest cost, which was offset by lower tax rate.
- FY20, revenue/ EBITDA/PAT grew 19%/25%/11% YoY.
- 4QFY20 exports/CSM revenue increased ~12% YoY (to INR6.8b) on proactive raw material inventory management and capacity planning. This, despite the unavailability of one multi-product and disrupted global supply chain. The COVID-19 pandemic disrupted operations and movement of goods, resulting in partial deferment of revenue to 1QFY21.
- Domestic agrochemicals' revenue declined 12% YoY (to INR1.7b) due to product positioning plans getting impacted by COVID-19.
- There was no major impact on financials due to COVID-19, barring the shortfall in 4QFY20 revenue by INR1b (mainly domestic agrochemicals) and EBITDA impact of INR220m; the shortfall should recover in 1QFY21. Excluding the above impact, revenue/EBITDA would have grown 19%/20% in 4QFY20.
- For FY20, CFO grew 79% YoY to INR7b on the back of better operating performance and release of working capital. Decrease in debtor days and increase in payable days was partly offset by increase in inventory days.

Highlights from management commentary

- FY21 capex stands at INR6b, majority of which is toward organic growth. PI is evaluating inorganic acquisition opportunities – likely in pharma.

- PI has tied up with few large pharma companies in Japan and India, and supplies should start from 1QFY21. PI has successfully developed and scaled up advance intermediate for a COVID-19 drug. This marks PI's entry into the pharma value chain. Revenue contribution from pharma is expected at 11-15% over the next few years.
- The company has guided for 20%+ revenue growth in FY21 (including the Isagro acquisition).
- Order book stood at ~USD1.5b (v/s USD1.4b as at 3QFY20), which provides high visibility of sustainable growth over the next 3-5 years.

Valuation and view

- PI closed FY20 on a strong note with revenue/EBITDA growth of 19%/25% YoY, mainly driven by 31% revenue growth in the CSM business. For FY21, management remains confident of achieving 20%+ revenue growth.
- We believe the company has levers in place for sustaining growth momentum in the near term due to (a) its recently commenced two multi-purpose plants ramping up operations, (b) revenue from the Isagro acquisition, (c) sustaining growth momentum in the CSM business on the back of strong USD1.5b order book, and (d) product launches in the domestic market (2-3 every year), thereby providing earnings visibility.
- Additionally, PI has successfully marked its entry into the pharma value chain by tying up with a few large pharma companies in Japan and India, thus garnering an additional growth lever.
- We maintain our estimates for FY21/FY22E and value the stock at 30x FY22E EPS to arrive at a TP of INR1,835, implying 15% upside.

Quarterly Earning Model


Y/E March	FY19				FY20				(INR M)			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	FY19	FY20	FY20	Var (%)
Net Sales	6,056	7,230	7,075	8,048	7,541	9,074	8,498	8,552	28,409	33,665	9,645	-11
YoY Change (%)	9.5	28.9	31.6	28.7	24.5	25.5	20.1	6.3	24.8	18.5	19.8	
Total Expenditure	4,875	5,881	5,583	6,313	6,027	7,149	6,633	6,689	22,644	26,487	7,561	
EBITDA	1,181	1,349	1,492	1,735	1,514	1,925	1,865	1,863	5,765	7,178	2,083	-11
Margins (%)	19.5	18.7	21.1	21.6	20.1	21.2	21.9	21.8	20.3	21.3	21.6	
Depreciation	220	229	235	245	294	317	319	436	930	1,367	320	
Interest	17	14	9	10	26	25	38	84	50	170	45	
Other Income	102	124	147	221	123	109	191	68	594	489	200	
PBT before EO expense	1,046	1,230	1,395	1,701	1,317	1,692	1,699	1,411	5,379	6,130	1,918	
Extra-Ord expense	0	0	0	0	0	0	0	0	0	0	0	
PBT	1,046	1,230	1,395	1,701	1,317	1,692	1,699	1,411	5,379	6,130	1,918	
Tax	229	284	318	444	309	461	487	312	1,277	1,572	440	
Rate (%)	21.9	23.1	22.8	26.1	23.5	27.2	28.7	22.1	23.7	25.6	22.9	
Minority Interest & Profit/Loss of Asso. Cos.	0	0	0	0	0	-1	1	-8	0	-8	0	
Reported PAT	817	946	1,077	1,257	1,008	1,232	1,211	1,107	4,102	4,566	1,478	
Adj PAT	817	946	1,077	1,257	1,008	1,232	1,211	1,107	4,102	4,566	1,478	-25
YoY Change (%)	-18.4	17.9	33.6	19.2	23.4	30.2	12.4	-11.9	12.0	11.3	18.8	
Margins (%)	13.5	13.1	15.2	15.6	13.4	13.6	14.3	12.9	14.4	13.6	15.3	

Key Performance Indicators

Y/E March	FY19				FY20				FY19	FY20
Particulars	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q		
CSM Revenue (INRm)	3,152	4,190	5,410	6,103	5,011	6,386	6,438	6,830	18,840	24,660
% Change	5.1	38.1	40.2	39.3	59.0	52.4	19.0	11.9		30.9
Domestic Formulation (INRm)	2,908	3,040	1,661	1,945	2,530	2,688	2,060	1,720	9,569	9,000
% Change	23.0	24.0	9.5	4.0	-13.0	-11.6	24.0	-11.6		-5.9
Cost Break-up										
RM Cost (% of sales)	53.4	57.0	53.4	54.3	55.2	57.6	53.4	53.2	54.6	54.9
Staff Cost (% of sales)	10.9	9.5	9.1	8.1	10.2	8.0	9.0	11.1	9.3	9.5
Other Cost (% of sales)	16.2	14.8	16.5	16.1	14.5	13.2	15.7	13.9	15.8	14.3
Gross Margins (%)	46.6	43.0	46.6	45.7	44.8	42.4	46.6	46.8	45.4	45.1
EBITDA Margins (%)	19.5	18.7	21.1	21.6	20.1	21.2	21.9	21.8	20.3	21.3
EBIT Margins (%)	15.9	15.5	17.8	18.5	16.2	17.7	18.2	16.7	17.0	17.3


Key Exhibits

Exhibit 1: Revenue growth trend




Source: Company, MOFSL

Exhibit 2: EBITDA trend




Source: Company, MOFSL

Exhibit 3: PAT trend




Source: Company, MOFSL

Exhibit 4: CSM revenue trend



Source: Company, MOFSL

Exhibit 5: Agri-input revenue trend



Source: Company, MOFSL

Exhibit 6: Key operational highlights– FY20

	Capacity Build-up	- Commissioned 2 new MPPs - Stabilized 1st full year OPS of MPP-8 - Commenced construction of 2 new MPPs to get completed in FY22 and FY23		New Product Launch	Launched 3 new products including one wheat herbicide "AWKIRA" and got very good market response
	New Enquiry/Scale-up	5 new products >70 new enquiries; ~20% in non-agchem area ~60 molecules in ~R&D pipeline		Label expansion /product penetration	- Submission of reg Dossier for New miticide - Aggr. Positioning of OSHEEN into cotton - COSKO in rice to fill gap of Phorate 10G
	Customer Acquisition & Order book	- Initiated commercial scale business with 3 new customers - Order book position >\$1.5 billion		Portfolio Optimisation Strategy	- Withdrawal of 5 EOLC products from portfolio - Signed agreement to in-license 2 new products for farm and PPM segment
	Technology Scaleup	- Flow Chem, Pressure filtration, Continuous fluidized drying, etc - Advanced analytics based tools to improve plant efficiency		Farm Application Services - Successful piloting of new business model	150 Spray Machines on ground sourced from Japan - Encouraging response from farmers
	M&A Transaction	- Acquired Isagro Asia - Evaluating few other strategic option		Digitalisation and process improvement	- Launched M Power for field force mgmt and CRM - Launched Track and trace App by installing QR codes in key products
				IPR Creation	Filed 22 patents during the year

Source: Company, MOFSL

Exhibit 7: Isagro acquisition plan

The Plan	Our Aim	Major Levers
- Domestic Marketing Piece → Merge with GIVAGRO (100% Sub of PI) - Manufacturing / CM Piece → Merge with PI Merger activities are expected to get completed in Q4FY21. Repurposing of mfg site expected to get completed by end of year.	JIVAGRO - To be one of the leading players in the horticulture segment in India >20% CAGR growth over next 4-5 years	- Portfolio of existing and pipeline products providing end to end crop solutions, anchored in specialty and biologicals. - Specialized marketing channel, field force and customer connect in this segment - Cross leveraging PI's specialized product portfolio for horticulture - Differentiated GTM by crop, expertise based digitally enabled front-end
	MFG SITE - Repurpose current mfg set up to align with PI's CSM exports - Enhance capacity utilization from current 20-25% to >90% to more than triple the revenue generation in next couple of years.	- Pipeline products of PI's CSM exports requiring scale up and commercialisation - In-sourcing of some of the outsourced intermediates to build a sustainable supply chain of existing products. - Synergies with PI's neighbouring operations in Mfg, sourcing, EHS, Quality, IT and other functions.

Source: Company, MOFSL

Exhibit 8: Growth levers for PI

inspired by nature

FY21 started on a positive note with entry into Pharma value chain !!

**Good start for Domestic Agri Input
Expected to do well in a growing market**

CSM Exports to continue growth momentum

Strategic direction and priorities remain intact while carefully transitioning thru Covid-19 uncertainties

- Successfully developed and scaled up adv intermediate for a **promising Covid-19 Drug!**
- Business tied up with few large Pharma comps in Japan & India; supplies to start from Q1FY21
- R&D team working on some key technologies paving way many other intermediates / drugs

- Weatherman predicting normal South-West Monsoon...
- GOI economic package for farmers is expected to drive agriculture growth, improve liquidity
- April / May govt data shows steep growth in agri inputs sale; Increased acreages of key crops
- PI is in a good position to share market growth opportunity with renewed GTM strategy (post Isagro acquisition), Portfolio of market leading brands and experienced team.

- All global customers giving positive commentary; no change in demand forecast
- Volume Scale up expected for some of the products commercialized in last 1-2 years.
- 2 newly commissioned MPPs to get full scale operations in FY21
- Promising products in R&D pipeline ; progress impacted due to Covid-19, should get pace in Q2
- Order book remained robust @ ~US\$ 1.5 Bn; high visibility of sustainable growth over 3-5 yrs

- Pursue inorganic growth opportunities to diversify into adjacencies, widen technology portfolio and de-risk operations
- Build new IP building for deepening our technological capabilities, de-risking current operations and opening up newer opportunities
- Raise Capital to seize growth opportunities while maintaining strong balance sheet & liquidity in uncertain times.

Source: Company, MOFSL



Management call highlights

Custom Synthesis and Manufacturing (CSM) business:

- Inquiry flows have increased due to the China issue.
- Generally, it takes 2-3 years to commercialize a new molecule by working alongside customers.
- Order book stood at ~USD1.5b, which provides high visibility for sustainable growth over 3-5 years.
- PI commenced two multi-purpose plants in FY20.
- Exports registered solid ~30% growth YoY by volume scale-up of few existing products and commercializing five new products.

Domestic agrochemicals:

- Domestic revenue declined 12% YoY (to INR1.7b) due to product positioning plans getting impacted by COVID-19.
- Price increase has been taken in selective products for the upcoming Kharif season in the domestic market.
- Products launched in the last 2-3 years contributed 30-35% of sales.
- Osheen product going generic could be challenged by the company (could be taken up with government authorities).

Pharma

- PI has tied up with few large pharma companies in Japan and India, and supplies should start from 1QFY21. PI has successfully developed and scaled up advance intermediate for a COVID-19 drug. This marks PI's entry into the pharma value chain.

- Revenue contribution from pharma is expected at 11-15% over the next few years.
- The company's plant has not gone through any regulatory approvals as they manufacture intermediates.

Others

- Isagro's revenue for the quarter stood at INR600m – INR330m from domestic and the balance from exports.
- Guidance for FY21 – revenue growth of 20%+.
- FY21 capex stands at INR6b, majority of which is toward organic growth. The company is evaluating inorganic acquisition opportunities – likely in pharma. First quarter performance of Isagro Asia (post acquisition) was consolidated with PI; business registered ~10% YoY growth.

Valuation

- PI closed FY20 on a strong note with revenue/EBITDA growth of 19%/25% YoY, mainly driven by 31% revenue growth in the CSM business. For FY21, management remains confident of achieving 20%+ revenue growth.
- We believe the company has levers in place for sustaining growth momentum in the near term due to (a) its recently commenced two multi-purpose plants ramping up operations, (b) revenue from the Isagro acquisition, (c) sustaining growth momentum in the CSM business on the back of strong USD1.5b order book, and (d) product launches in the domestic market (2-3 every year), thereby providing earnings visibility.
- Additionally, PI has successfully marked its entry into the pharma value chain by tying up with a few large pharma companies in Japan and India, thus garnering an additional growth lever.
- We maintain our estimates for FY21/FY22E and value the stock at 30x FY22E EPS to arrive at a TP of INR1,835, implying 15% upside.

Exhibit 9: Change in estimates

Earnings Change (INR m)	Old		New		Change	
	FY21E	FY22E	FY21E	FY22E	FY21E	FY22E
Revenue	44,315	52,146	44,796	53,684	1%	3%
EBITDA	9,658	12,052	9,817	12,505	2%	4%
Adj. PAT	6,614	8,273	6,353	8,437	-4%	2%

Source: MOFSL

Financials and valuations

Income Statement (Consolidated)

(INR M)

Y/E March	FY16	FY17	FY18	FY19	FY20	FY21E	FY22E
Net Revenue	20,963	22,768	22,771	28,409	33,665	44,796	53,684
Change (%)	8.0	8.6	0.0	24.8	18.5	33.1	19.8
EBITDA	4,312	5,533	4,934	5,764	7,178	9,817	12,505
Margin (%)	20.6	24.3	21.7	20.3	21.3	21.9	23.3
Depreciation	543	730	830	930	1,367	1,714	1,883
EBIT	3,770	4,802	4,104	4,834	5,811	8,103	10,623
Int. and Finance Charges	96	72	53	50	170	355	285
Other Income	355	366	603	595	489	611	764
PBT bef. EO Exp.	4,028	5,096	4,653	5,379	6,130	8,359	11,101
EO Items	0	0	0	0	0	0	0
PBT after EO Exp.	4,028	5,096	4,653	5,379	6,130	8,359	11,101
Current Tax	909	1,035	1,001	1,176	1,259	2,006	2,664
Deferred Tax	4	-534	-22	101	313	0	0
Tax Rate (%)	22.7	9.8	21.0	23.7	25.6	24.0	24.0
Less: MI/Profit & Loss of associates	0	1	-2	0	-8	0	0
Reported PAT	3,116	4,594	3,676	4,102	4,566	6,353	8,437
Adjusted PAT	3,116	4,594	3,676	4,102	4,566	6,353	8,437
Change (%)	26.7	47.5	-20.0	11.6	11.3	39.1	32.8
Margin (%)	14.9	20.2	16.1	14.4	13.6	14.2	15.7

Balance Sheet (Consolidated)

(INR M)

Y/E March	FY16	FY17	FY18	FY19	FY20	FY21E	FY22E
Equity Share Capital	137	138	138	138	138	138	138
Total Reserves	11,572	16,134	19,111	22,716	26,053	31,313	38,657
Net Worth	11,709	16,272	19,248	22,854	26,191	31,451	38,795
Total Loans	1,514	1,198	834	99	5,077	5,077	4,077
Capital Employed	13,576	17,470	20,082	22,953	31,370	36,630	42,974
Gross Block	11,503	12,942	14,298	17,109	24,366	28,366	32,366
Less: Accum. Deprn.	2,762	3,492	4,322	5,252	6,619	8,332	10,215
Net Fixed Assets	8,742	9,450	9,977	11,857	17,747	20,033	22,151
Capital WIP	713	773	899	1,828	1,828	3,828	4,328
Current Investments	0	824	1,595	1,119	1,325	0	0
Total Investments	3	833	1,607	1,291	1,504	1,004	2,004
Curr. Assets, Loans&Adv.	10,028	11,760	13,515	16,431	21,169	24,800	29,839
Inventory	3,948	4,320	4,520	5,357	7,989	8,591	10,295
Account Receivables	3,978	4,237	5,268	6,618	6,465	9,205	11,031
Cash and Bank Balance	560	1,326	1,307	892	1,342	1,181	1,534
Loans and Advances	1,543	1,877	2,420	3,564	5,373	5,823	6,979
Curr. Liability & Prov.	5,910	5,544	6,182	8,595	10,878	13,035	15,348
Account Payables	3,661	2,878	3,687	5,130	5,909	7,112	8,358
Provisions	196	316	340	416	548	548	548
Net Current Assets	4,118	6,216	7,333	7,836	10,291	11,765	14,491
Appl. of Funds	13,576	17,470	20,082	22,953	31,370	36,630	42,974

Financials and valuations

Ratios

Y/E March	FY16	FY17	FY18	FY19	FY20	FY21E	FY22E
Basic (INR)							
EPS	22.7	33.4	26.7	29.7	33.1	46.1	61.2
Cash EPS	26.7	38.7	32.7	36.5	43.0	58.5	74.8
BV/Share	85.4	118.3	139.6	165.7	189.9	228.1	281.3
DPS	3.1	4.0	5.5	4.0	4.0	6.5	6.5
Payout (%)	16.6	14.6	25.1	16.4	14.7	17.2	13.0
Valuation (x)							
P/E	70.0	47.6	59.7	53.5	48.1	34.5	26.0
Cash P/E	59.6	41.1	48.7	43.6	37.0	27.2	21.3
P/BV	18.6	13.5	11.4	9.6	8.4	7.0	5.7
EV/Sales	10.5	9.6	9.6	7.7	6.6	5.0	4.1
EV/EBITDA	51.1	39.6	44.4	37.9	31.1	22.7	17.7
Dividend Yield (%)	0.2	0.3	0.3	0.3	0.3	0.4	0.4
FCF per share	3.8	14.8	13.9	3.8	-2.0	5.7	27.1
Return Ratios (%)							
RoE	29.9	32.8	20.7	19.5	18.6	22.0	24.0
RoCE	27.1	30.4	19.8	19.2	17.3	19.5	21.8
RoIC	27.4	32.3	21.0	20.9	18.9	21.5	24.6
Working Capital Ratios							
Asset Turnover (x)	1.5	1.3	1.1	1.2	1.1	1.2	1.2
Inventory (Days)	69	69	72	69	87	70	70
Debtor (Days)	66	65	83	85	70	75	75
Creditor (Days)	115	90	115	121	117	105	105
Working Cap. Turnover (Days)	62	78	97	89	97	86	88
Leverage Ratio (x)							
Current Ratio	1.7	2.1	2.2	1.9	1.9	1.9	1.9
Interest Cover Ratio	39	67	77	97			
Debt/Equity	0.1	0.1	0.04	0.00	0.2	0.2	0.1

Cash Flow Statement (Consolidated)

Y/E March	FY16	FY17	FY18	FY19	FY20	FY21E	FY22E
OP/(Loss) before Tax	4,028	5,096	4,653	5,379	6,130	8,359	11,101
Depreciation	543	730	830	930	1,367	1,714	1,883
Interest & Finance Charges	96	72	53	50	170	355	285
Direct Taxes Paid	-909	-1,035	-1,001	-1,176	-1,259	-2,006	-2,664
(Inc)/Dec in WC	114	-1,332	-1,136	-918	573	-1,635	-2,374
CF from Operations	3,872	3,533	3,399	4,265	6,981	6,787	8,231
Others	0	0	0	0	0	0	0
CF from Operating incl EO	3,872	3,533	3,399	4,265	6,981	6,787	8,231
(inc)/dec in FA	-3,345	-1,499	-1,482	-3,739	-7,257	-6,000	-4,500
Free Cash Flow	527	2,034	1,918	525	-276	787	3,731
(Pur)/Sale of Investments	1	-830	-774	316	-213	500	-1,000
Others	0	-198	-69	126	4,600	0	0
CF from Investments	-3,344	-2,527	-2,325	-3,298	-2,870	-5,500	-5,500
Issue of Shares	1	0	0	0	0	0	0
Inc/(Dec) in Debt	366	-315	-365	-735	4,978	0	-1,000
Interest Paid	-96	-72	-53	-50	-170	-355	-285
Dividend Paid	-518	-671	-924	-672	-673	-1,093	-1,093
Others	-40	818	248	75	-7,797	0	0
CF from Fin. Activity	-288	-240	-1,094	-1,382	-3,661	-1,448	-2,378
Inc/Dec of Cash	240	766	-19	-415	450	-161	353
Opening Balance	320	560	1,326	1,307	892	1,342	1,181
Closing Balance	560	1,326	1,307	892	1,342	1,181	1,534

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Investment Advisory Services, Depository participant services & distribution of various financial products. MOFSL is a subsidiary company of Passionate Investment Management Pvt. Ltd.. (PIMPL). MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act") and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co.Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company
- received compensation/other benefits from the subject company in the past 12 months
- other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 71934200/ 022-71934263; Website www.motilaloswal.com CIN no.: L67190MH2005PLC153397. Correspondence Office Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad(West), Mumbai- 400 064. Tel No: 022 7188 1000.

Registration Nos.: Motilal Oswal Financial Services Limited (MOFSL)*: INZ000158836(BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN - 146822; Investment Adviser: INA000007100; Insurance Corporate Agent: CA0579;PMS:INP000006712. Motilal Oswal Asset Management Company Ltd. (MOAMC): PMS (Registration No.: INP000000670); PMS and Mutual Funds are offered through MOAMC which is group company of MOFSL. Motilal Oswal Wealth Management Ltd. (MOWML): PMS (Registration No.: INP000004409) is offered through MOWML, which is a group company of MOFSL. Motilal Oswal Financial Services Limited is a distributor of Mutual Funds, PMS, Fixed Deposit, Bond, NCDs, Insurance Products and IPOs. Real Estate is offered through Motilal Oswal Real Estate Investment Advisors II Pvt. Ltd. which is a group company of MOFSL. Private Equity is offered through Motilal Oswal Private Equity Investment Advisors Pvt. Ltd which is a group company of MOFSL. Research & Advisory services is backed by proper research. Please read the Risk Disclosure Document prescribed by the Stock Exchanges carefully before investing. There is no assurance or guarantee of the returns. Investment in securities market is subject to market risk, read all the related documents carefully before investing. Details of Compliance Officer: Name: Neeraj Agarwal, Email ID: na@motilaloswal.com, Contact No.: 022-71881085.

* MOSL has been amalgamated with Motilal Oswal Financial Services Limited (MOFSL) w.e.f August 21, 2018 pursuant to order dated July 30, 2018 issued by Hon'ble National Company Law Tribunal, Mumbai Bench.